Amnio-Maxx amnion patch for long-lasting diabetic foot ulcers
Tests Amnio-Maxx patch plus usual care for non-healing diabetic foot ulcers in adults.
Key facts
- Who runs it
- Royal Biologics
- Where
- Burbank, Carrollton, East Patchogue, Miami, Omaha, Spicewood, Stone Mountain, and Tulsa, United StatesSee the 8 sites
- Trial code
- Registry title
- Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 248 people, planned
- Started
- 14 Aug 2025
- Planned end
- 14 Aug 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- Amnio-Maxx® Dual Layer Amnion Patch
- Standard of Care (Investigator Choice)
- Record updated
- 7 October 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 1 or type 2 diabetes who have a foot ulcer that is not healing. It compares the Amnio-Maxx® Dual Layer Amnion Patch plus standard care with standard care alone.
- Age
- 18 years or older. At least 50% of people in the trial must be over 65 years.
- Sex
- All sexes can join.
- Disease stage
- A diabetic foot ulcer of Wagner grade 1 or 2, at or below the inner ankle bone. It has been present for more than 4 weeks but less than 12 months. It measures 1.0 cm2 to 25 cm2 after cleaning. It healed less than 20% during the 2-week screening period. Blood flow to the foot must be good enough on a test. The ulcer base must be clean, without dead tissue. Any past infection must be treated and under control.
- Earlier treatment
- Diabetes must be treated with tablets and/or insulin. The ulcer must have been off-loaded with the trial's pressure-relief device for at least 14 days before the start. No tissue-engineered or scaffold products on the ulcer in the last 30 days. No immunosuppressants, steroids over 10mg a day, chemotherapy or steroid creams on the ulcer within 30 days before the start.
Main reasons for not taking part
- Expected to live less than 1 year.
- Ulcer shrank by 20% or more during the 2 weeks of screening.
- Major uncontrolled illness, such as serious heart, kidney, liver or lung disease, lupus or sickle cell anemia, or palliative care.
- Being treated for active cancer, or past cancer in the ulcer.
- Pregnant or breastfeeding, or allergic to amniotic tissue or Amnio-Maxx parts.
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Potential subjects are required to meet all the following criteria for enrollment into the study and subsequent randomization
- The potential subject is 18 years of age or older. At least 50% of the enrolled population must be > 65 years of age
- The potential subject has a history of Type I or Type II Diabetes Mellitus requiring treatment by a physician with either oral medications and/or insulin replacement therapy
- Potential subjects have an ulcer characterized by the following:; Presence of a diabetic foot ulcer Wagner 1 or 2 grade at the first screening visit on any aspect of the foot, provided it is at or below the aspect of the medial malleolus. [NOTE: If two or more DFUs are present with the same grade, the index ulcer is the largest ulcer and the only one evaluated in the study. Index ulcer must be more than 5 cm distant apart.]; A diabetic foot ulcer present for greater than 4 weeks (documented in the medical record) but less than 12 months duration if being treated with active SOC
- Objectively, less than 20% healing in the two-week screening period prior to randomization
- Study ulcer is a minimum of 1.0cm2 and a maximum of 25 cm2 post-debridement at first treatment visit
- Index ulcer and/or index ulcer limb may have had prior infection, but infection(s) must be adequately treated and controlled as defined by IDSA Guidelines Grade level 1
- The subject is able and willing to follow the protocol requirements
- Subject has signed informed consent. Adequate circulation to the affected foot as demonstrated by a dorsum transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 30 mmHg; an ABI between 0.7 and ≤ 1.3, or TBI of >6 within 3 months of the first Screening Visit
- Negative pregnancy test for females of childbearing potential (e.g., not post- menopausal for at least one year or surgically sterile). Females of childbearing potential must be willing to use acceptable methods of contraception (birth control methods, barriers, or abstinence) starting at Screening and continuing through the duration of their study participation
- The index ulcer has been offloaded with protocol defined offloading device throughout the study run-in period for at least 14 days prior to randomization (Run-in period defined as Screening through TV1/Randomization)
- The index ulcer has a clean base and is free of necrotic debris at time of placement of treatment product
Who cannot take part
- The Subject has other concurrent conditions that in the opinion of the Principal Investigator may compromise subject safety
- Concurrent participation in another clinical trial that involves an investigational drug or device that would interfere with this study
- Subjects with a history of more than two weeks treatment with immunosuppressants (including systemic corticosteroids
- >10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within 30 days prior to randomization visit or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study
- Index ulcer has been previously treated with tissue engineered materials (e.g. Apligraf® or Dermagraft®) or other scaffold materials (e.g. Oasis, Matristem) within the last 30 days preceding the first treatment visit; -
- Index ulcer has been present for >1 year
- Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence to medical treatment
- Subject has major uncontrolled medical disorders such as serious cardiovascular, renal, liver or pulmonary disease, lupus, palliative care or sickle cell anemia
- Subject currently being treated for an active malignant disease
- or subjects with history of malignancy within the ulcer
- Known contraindications to amniotic tissue membranes or known allergies to any of the Amnio-Maxx components
- Index ulcer has reduced in area by 20% or more after 2 weeks of standard of care from the first screening visit (S1) to the TV1/randomization visit
- The Subject has a known life expectancy of < 1 year
- Patient does not have adequate 2-week historical data demonstrating < 20% area reduction
- Subject is unable to comply with offloading device
- Subject has ulcers that are completely necrotic or fibrotic tissue
- Subject is pregnant or breastfeeding
This trial is currently available in United States.
- Lion Heart Clinical ResearchBurbank, United StatesContact: Nicole SchrecngostTaking people
- VAST Clinical Research Carrollton Foot CenterCarrollton, United StatesContact: Nicole SchrecngostTaking people
- Suffolk Foot and AnkleEast Patchogue, United StatesContact: Nicole SchrecngostTaking people
- Royal Research SouthMiami, United StatesContact: Nicole SchrecngostTaking people
- SerenaGroup Research CenterOmaha, United StatesContact: Nicole SchrecngostTaking people
- Elite Foot & Ankle AssociatesSpicewood, United StatesContact: Nicole SchrecngostTaking people
- Denali Health Atlanta, LLCStone Mountain, United StatesContact: Nicole SchrecngostTaking people
- Wound Care of TulsaTulsa, United StatesContact: Nicole SchrecngostTaking people
About the trial
What the trial wants to find out
This study will evaluate a cellular, acellular, matrix-like product (CAMP) and Standard of Care (SOC) versus SOC alone in the closure of nonhealing diabetic foot ulcers (DFUs). The study will evaluate Amnio-Maxx® Dual Layer Amnion Patch.
The 2 groups in the trial
- Standard of CareTreatment being tested
Cleansing, debridement, wound documentation, off-loading
Treatment: Standard of Care (Investigator Choice)
- Amnio-Maxx® Dual Layer Amnion PatchTreatment being tested
Application of Amnio-Maxx® Dual Layer Amnion Patch
Treatment: Amnio-Maxx® Dual Layer Amnion Patch and Standard of Care (Investigator Choice)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Controlled Multicenter Trial, Examining the Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers.
- Plain-language title
- Amnio-Maxx amnion patch for long-lasting diabetic foot ulcersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 7 October 2025